Immunotoxicity Considerations for Next Generation Cancer Nanomedicines

Advanced Science

Neill J. Liptrott¹  Joanne Lysaght²  Gary Hannon³  Adriele Prina‐Mello³ 

[1] Department of Molecular and Clinical Pharmacology Institute of Translational Medicine The University of Liverpool Liverpool L69 3GF UK;Department of Surgery TTMI Trinity College Dublin Dublin 8 Ireland;Nanomedicine and Molecular Imaging Group Trinity Translational Medicine Institute (TTMI) Trinity College Dublin Dublin 8 Ireland;

关键词: cancer;    immunotoxicity;    nanomedicine;    regulation;    safety;   

DOI  :  10.1002/advs.201900133

来源: DOAJ

【 摘 要 】

Abstract Although interest and funding in nanotechnology for oncological applications is thriving, translating these novel therapeutics through the earliest stages of preclinical assessment remains challenging. Upon intravenous administration, nanomaterials interact with constituents of the blood inducing a wide range of associated immunotoxic effects. The literature on the immunological interactions of nanomaterials is vast and complicated. A small change in a particular characteristic of a nanomaterial (e.g., size, shape, or charge) can have a significant effect on its immunological profile in vivo, and poor selection of specific assays for establishing these undesirable effects can overlook this issue until the latest stages of preclinical assessment. This work describes the current literature on unintentional immunological effects associated with promising cancer nanomaterials (liposomes, dendrimers, mesoporous silica, iron oxide, gold, and quantum dots) and puts focus on what is missing in current preclinical evaluations. Opportunities for avoiding or limiting immunotoxicity through efficient preclinical assessment are discussed, with an emphasis placed on current regulatory views and requirements. Careful consideration of these issues will ensure a more efficient preclinical assessment of cancer nanomedicines, enabling a smoother clinical translation with less failures in the future.

【 授权许可】

Unknown